ABSTRACT
INTRODUCTION
Chronic Lymphocytic Leukemia (CLL) is a low-grade lymphoproliferative tumor, which is characterized by monoclonal B lymphocytes accumulation, apoptosis inhibition as well as infiltration of peripheral blood, bone marrow and lymph nodes. 1 A large number of evidences suggested that the CD4 + T cell-mediated autoimmune regulator imbalance may play a key role in the pathogenesis and development of CLL. + T cell. Th17 cell is an important mediator of cancer, chronic inflammation and autoimmune diseases through secretion of proinflammation cytokines, such as IL-17A, IL-17F, IL-22, IL-21 and IFN-γ. 4, 5 Treg cell plays a role in antiinflammatory and maintain autoimmune tolerance, which also shows negative immuno-regulatory function via cell-contact inhibition and secretion of inhibitory cytokines (such as IL-10, TGF-β). 6 Both of Th17 and Treg cells can be activated by autoimmune or inflammation-mediated immune response. 7 Lots of studies have shown that Th17/Treg imbalance played an important role in autoimmune diseases and tumorigenesis. 8, 9 However, until now, there are no follow-up on cell level of CLL in China. Our primary results showed that the frequency of Th17 cells was elevated and the frequency of Treg cells was reduced in the peripheral blood of CLL patients.
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In this study, we evaluated the cytokines secreted by Th17 and Treg cells in the peripheral blood of CLL patients. Furthermore, we followed up the frequencies of Treg and Th17 cells in patients with CLL (Rai stage III and IV, Rai stage: cytologic staging system for chronic lymphocytic leukemia, which divides it into low (0), intermediate (I and II), and high-risk stages (III and IV). Cell preparation: For analysis of Th17, 500 μl of whole blood sample was cultured in complete culture medium (RPMI 1640 supplemented with 10% heat-inactivated fetal calf serum) for 4 h, in the presence of phorbol myristate acetate (PMA, PMA is used to stimulate the intracellular cytokine production together with ionomycin, 50 ng/ml, Sigma, USA), ionomycin (1 μg/ml, Sigma, USA) and monensin (a polyether antibiotic, 1 μg/ml, BD, USA). The incubators were set at 37°C, 5% CO 2 . For analysis of Treg, 50 μl of whole blood sample was aliquoted into a tube for further staining. Surface and intracellular staining: For Th17 analysis, 70 μl of stimulated whole blood was 
METHODS

Patients
RESULTS
Plasma concentrations of cytokines in patients with CLL:
As shown in Table- 
Change in Treg and Th17 cell numbers in Rai III and IV CLL patients at 12 month follow-up:
Twenty CLL patients at Rai stage III and IV were followed for one year, at which time 14 patients continued in the study. Five patients dropped out of the study to receive treatment in other hospitals, and one patient could no longer be contacted. We tested lymphocyte numbers, CD4+ and CD8+ T cells ratios (Fig.1) , and Treg and Th17 cell frequencies (Fig.2 ) in patients after 3, 6, and 12 months (M3, M6, M12) of constant standard treatment with chlorambucil (Gloxo SmithKline, UK). Flow cytometric analysis of a typical patient is shown in Fig.3 . After treatment for 3 months, the number of lymphocytes was significantly decreased compared to pretreatment numbers (12 
DISCUSSION
CLL is uncommon in China, with an incidence of only 1/20-1/30. In recent years, an increasing number of patients have been diagnosed with CLL, most of whom were evaluated at middle or late stage upon first visit. Several studies have shown significant degradation of T lymphocyte function and ratios in patients with B-cell CLL, 11 but the underlying cellular and molecular mechanisms for these changes are still unclear.
In our primary study, we found that the number of CD4+ T cells in the peripheral blood of CLL patients was elevated, and that therapy reduced the aberrant ratio of these cells. 10 However, our one year follow-up of Rai stage III and IV CLL patients showed no significant change in the number of peripheral CD4+ and CD8+ T cells. One possible reason is that only a partial number of patients were in complete remission after one year treatment, or alternatively, that the notable reduction in peripheral lymphocytes may have altered CD4+ T cell proportions.
This study also showed that the concentrations of IL-6, IL-17 and IL-23 were all significantly higher in CLL patients, while concentrations of Th17 in patients with CLL 14 The disagreement between our results and other studies may be due to several reasons including statistical methods (absolute count vs. relative proportion), race, and unbalanced autoimmune function after short term treatment. We plan to continue our follow-up study utilizing a larger population and a longer treatment term.
Reports of Th17 cells have also been contradictory. Jadidi-Niaragh et al. showed a lower frequency of Th17 cells in CLL patients, 15 but Jain et al. reported that the frequency of Th17 cells in peripheral blood and spleen cell suspensions was higher in patients with CLL. 16 In our study, there was no significant change in Th17 cells after three months treatment, but Th17 cell frequency gradually declined as patients continued to receive treatment. This result is in accordance with our primary result, and further suggested that the frequency of Th17 cells in patients with CLL was initially upregulated, followed by down regulation after treatment. 
Th17 in patients with CLL
Our results indicate that Th17 cells may play a key role in the CLL pathogenesis and progression, but the signaling pathways associated with these effects remain unclear. A recent study suggested that Th17 cells exert an anti-viral effect via activation of TGF-β and RORγt/RORα pathways. 17 Furthermore, the anti-tumor effect of Th17 may be related to the CXCL2 induction which was shown to occur downstream from IL-17RA-dependent induction of IL-1β.
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In conclusion, we found that patients with CLL in Sichuan province display a CD4+ cellmediated immune disorder. Th17 cells appear to be an important mediator of disease progression and require further study. Treg cell counts were decreased in the untreated patients and additional follow-up is needed to verify the role of Treg cells in CLL.
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